Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | PDE11A | Q9HCR9 | 2/20 | 0.41 |
| ▸ | CCR1 | P32246 | 2/20 | 0.40 |
| ▸ | MLYCD | O95822 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1721704 | 0.89 | DDR1 (0.44) | DDR1CCR1MLYCDMAPTMAOB | |
| SCHEMBL1721614 | 0.89 | DDR1 (0.44) | DDR1CCR1MLYCDMAPTMAOB | |
| SCHEMBL1721281 | 0.89 | DDR1 (0.44) | DDR1CCR1MLYCDMAPTMAOB | |
| SCHEMBL1721468 | 0.88 | DDR1 (0.43) | DDR1CCR1MLYCDMAPTMAOB | |
| SCHEMBL1723128 | 0.87 | DDR1 (0.42) | DDR1CCR1MLYCDMAPTMAOB | |
| SCHEMBL1722258 | 0.87 | DDR1 (0.42) | DDR1PDE4BPDE11ACCR1MLYCD | |
| SCHEMBL22497 | 0.87 | CCR1 (0.45) | PDE10APDE4BPDE11ACCR1MLYCD | |
| SCHEMBL19682 | 0.85 | CCR1 (0.42) | PDE10APDE4BPDE11ACCR1MLYCD | |
| SCHEMBL30795830 | 0.85 | CCR1 (0.42) | PDE10APDE4BPDE11ACCR1MLYCD | |
| SCHEMBL1721263 | 0.83 | DHODH (0.46) | DDR1CCR1MLYCDMAPTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399673-B2 | Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8399673-B2 | Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8399673-B2 | Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-03-19 | — | — | US | disclosed |
| US-20120252841-A1 | Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators | DRUNENTHAL GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252841-A1 | Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators | DRUNENTHAL GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252841-A1 | Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators | DRUNENTHAL GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| EP-2406229-A1 | SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010102811-A1 | SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010102811-A1 | SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2010-09-16 | — | — | WO | disclosed |
| US-20100234372-A1 | SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234372-A1 | SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234372-A1 | SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234372-A1 | SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | KCNQ1, KCNQ2, KCNJ2 | DDR1 4082/4885PDE10A 2549/4885PDE4B 1401/4885 |
| US-20120252841-A1 | Substituted 2-mercaptoquinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNJ2 | DDR1 4082/4885PDE10A 2549/4885PDE4B 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.